Management of Vaginal Spotting After One Year of Implanon Use

Initial Assessment and Reassurance

The Centers for Disease Control and Prevention recommends that patients be reassured that spotting after one year of Implanon use is generally not harmful, before systematically ruling out underlying gynecological problems and offering short-term medical treatment with NSAIDs or low-dose combined oral contraceptives/estrogen during bleeding days 1
Approximately 34% of women experience infrequent spotting throughout Implanon use, and unscheduled spotting or light bleeding is most common during the first year 1
The American College of Obstetricians and Gynecologists suggests providing reassurance that bleeding changes do not indicate a medical problem and may or may not decrease with continued implant use 1, 2

The Centers for Disease Control and Prevention recommends systematically evaluating for pregnancy, medication interactions, sexually transmitted diseases (STDs), and new pathologic uterine conditions, such as polyps or fibroids, if clinically indicated 1, 2, 3
If any underlying gynecological problem is identified, treat the condition or refer for appropriate care before attributing bleeding to the implant 1, 2, 3

The American College of Obstetricians and Gynecologists suggests offering NSAIDs for 5-7 days or low-dose combined oral contraceptives for 10-20 days during days of active bleeding, if no underlying gynecological problem is identified and the patient desires treatment 1, 2, 3
Estrogen alone for 10-20 days may also be considered, if medically eligible 1, 2, 3

The Centers for Disease Control and Prevention recommends counseling on alternative contraceptive methods and offering another method if desired, if irregular bleeding persists despite treatment and the patient finds it unacceptable 1, 2, 3

The American College of Obstetricians and Gynecologists advises against assuming all bleeding is benign, and recommends always ruling out pregnancy, STDs, and structural uterine pathology before attributing bleeding solely to the implant 1, 2, 3
The Centers for Disease Control and Prevention suggests not dismissing patient concerns, as bleeding significantly impacts quality of life and is a valid reason for method discontinuation if unacceptable to the patient 1, 2, 3